Adenocarcinoma

Oncology
5
Pipeline Programs
7
Companies
6
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
1
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 5 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

CP
Chugai PharmaJapan - Tokyo
1 program
1
BevacizumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT00548548Completed774Est. Nov 2013
CT
1 program
1
LM-302 InjectionPhase 31 trial
Active Trials
NCT07385703Not Yet RecruitingEst. May 2030
Corcept Therapeutics
Corcept TherapeuticsCA - Redwood City
1 program
1
Relacorilant 150 mg once dailyPhase 21 trial
Active Trials
NCT07259317Recruiting60Est. Jul 2027
Pfizer
PfizerNEW YORK, NY
1 program
1
ToriselPhase 1/21 trial
Active Trials
NCT00106353Completed71Est. Jan 2012
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
BIWA 4Phase 11 trial
Active Trials
NCT02204046Completed9
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
Extensive Intraperitoneal LavageN/A1 trial
Active Trials
NCT01476553Terminated30Est. Mar 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Chia Tai TianQing Pharmaceutical GroupLM-302 Injection
Chugai PharmaBevacizumab
Corcept TherapeuticsRelacorilant 150 mg once daily
PfizerTorisel
Boehringer IngelheimBIWA 4
Heidelberg PharmaExtensive Intraperitoneal Lavage

Clinical Trials (6)

Total enrollment: 944 patients across 6 trials

NCT07385703Chia Tai TianQing Pharmaceutical GroupLM-302 Injection

Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

Start: Mar 2026Est. completion: May 2030
Phase 3Not Yet Recruiting
NCT00548548Chugai PharmaBevacizumab

A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer

Start: Sep 2007Est. completion: Nov 2013774 patients
Phase 3Completed
NCT07259317Corcept TherapeuticsRelacorilant 150 mg once daily

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

Start: Jan 2026Est. completion: Jul 202760 patients
Phase 2Recruiting
NCT00106353PfizerTorisel

Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors

Start: Mar 2005Est. completion: Jan 201271 patients
Phase 1/2Completed
NCT02204046Boehringer IngelheimBIWA 4

Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Adenocarcinoma of the Breast

Start: Jan 20009 patients
Phase 1Completed
NCT01476553Heidelberg PharmaExtensive Intraperitoneal Lavage

Elimination of Peritoneal Tumor Cells With Extensive Peritoneal Lavage During Surgery in Patients With Gastric Cancer

Start: Feb 2011Est. completion: Mar 201330 patients
N/ATerminated

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
2m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
2m ago

Office Administrator

SystImmune
2m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
13m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
16m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
16m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 944 patients
7 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)